We’re excited to join Nasdaq Exchange to wrap up our R&D Day and the trading day by ringing the closing bell. #NasdaqListed

Dag Lodewijk Asscher, je bent het geweten van jouw partij. Nu is het moment om je uit te spreken.

Een onbegrijpelijk besluit van het Het Parool om Theodor Holman tegen zijn zin te laten stoppen met zijn column. Diep treurig: de best schrijvende columnist van Nederland. Grote dank voor alle jaren!

Simply increasing statin doses isn’t the best solution for persistently high LDL-C. Doubling the dose only reduces LDL-C by ~6%—a diminishing return even at dramatically higher doses. Combination therapy is significantly more effective for most patients.

ApoM? Never heard of it until today. Plays a role in Macular Degeneration? .Tucker Goodrich Josh nature.com/articles/s4146…

Eric Rodgers Tucker Goodrich Oh yeah ApoM is fascinating and is essential for incorporating small hydrophobic molecules like sphingosine-1 phosphate into HDL...however, there are 5 different S1p receptors!

Treating LDL is going to go the way treating hypertension did Combining multiple agents at lower doses instead of a high dose of one drug For example, Statin + ezetimibe or ezetimibe + CETP inhibitor or statin + PCSK9 inhibitor

Now what could cause that? 🤔 “The research suggests that "inflammaging"—chronic, low-grade inflammation associated with aging—appears to be a byproduct of industrialized lifestyles and varies significantly across global populations.” “Aging-related inflammation is not

Beg, borrow or Steal this paper so you can cruise down BROADWAY - there is a big need for this med 😅🧐- nejm.org/doi/pdf/10.105… National Lipid Association European Atherosclerosis Society ASPC European Society of Cardiology International Atherosclerosis Society (IAS) #cholesterol Family Heart Foundation NewAmsterdam Pharma Corporation

ESC late breakers you might be interested in Mon- presented by Jessica Schubert & Steve Nicholls. Sat 5.40 Science Box 5 - independent & joint effects of obesity & metabolic abnormalities on ASCVD, HF, MASLD and ESRD in males & females 1.9 m PY FU

P.D. Mangan Health & Freedom Maximalist 🇺🇸 Humans aren’t mice.

Hot off the press! Excited to share our new publication in #naturemedicine rdcu.be/evDC9 #ANGPTL3 #ANGPTL8 #lipids #ASCVD Targeting the specific ANGPTL3/8 complex to improve several dyslipidemias and possibly reduce residual cardiovascular risk

This paper is so important and puts to rest those jumping on the VLDL/remnant bandwagon at the expense of ignoring LDLs. What everyone needs to do is order apoB, a one-time Lp(a) and then work hard at lowering apoB. The treatments that lower apoB lower both remnant-P and LDL-P

Johnny Cash and John Denver perform "Take Me Home, Country Roads" in their only performance together (1978)

Obicetrapib is a selective CETPi which ⏬ LDL-C by ~36%. Now in AmericanHeartJ, we discuss the rational/design of the phase 3 REMBRANDT trial which will examine the effect of obicetrapib + ezetimibe on coronary plaque. sciencedirect.com/science/articl… John Kastelein Steve Nicholls

The curtain is about to rise at #AAIC2025, where full results from the Alzheimer’s biomarker prespecified analysis from our BROADWAY LDL-C lowering study will be shared in a Developing Topics oral presentation. Make plans to join us at AAIC: bit.ly/4lOSxBO

Het nieuwe handelsakkoord met de Verenigde Staten bevestigt wat al langer zichtbaar is: Europa heeft zijn energie-onafhankelijkheid verloren. Russisch gas is ingeruild voor Amerikaans LNG, duurder, vervuilender, en vooral een nieuwe vorm van structurele afhankelijkheid. Die

⭐️you really have to listen to Prof Kausik Ray FMedSci in this free podcast on lipids....

☺️*In conditions like the dyslipidemia of IR, with depletion of large HDL2, protective properties of the HDL class can be compromised" 🤓"We speculate that if present in vivo, this phenomenon may contribute to the athero-protective role of high circulating levels of HDL2"

solidrock Seems to me to it is an old guy living in the past, when there were no drugs other than statins. I am an even older guy, but a lot more progressive, who recognizes reducing MACE is all about apoB lowering and high-potency statins are no longer needed in most cases. Ezetimibe plus